Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutam...
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Retrospective study reinforces real-world efficacy of ERLEADA ® for patients with mCSPC HORSHAM, Pa. Feb. 2, 2026 /PRNewswire/ -- Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA ® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P =0.007). These findings reflecting patients treated in routine clinical practice are being presented at the 36th Annual International Prostate Cancer Update on February 2, where it was selected as a top abstract (Abstract #6). Designed to meet rigorous FDA guidance and robust methodological framework on real-world evidence, this study included a pre-specified protocol, pre-specified primary endpoint of overall surv
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF SymposiumBusiness Wire
- BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? [Yahoo! Finance]Yahoo! Finance
- Alcon's Precision7 Weekly Lenses Test Comfort Claims And Growth Hopes [Yahoo! Finance]Yahoo! Finance
- 5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/6/26 - Form 4
- 2/5/26 - Form 144
- 2/5/26 - Form SCHEDULE
- JNJ's page on the SEC website